LIGHTSENSE TECHNOLOGIES LTD

Their core work

LightSense Technologies is a London-based medical device startup specializing in laser-based systems for dermatology and aesthetic healthcare, with a particular focus on treating pigmentation disorders. They developed a proprietary light-based medical device and successfully commercialized it through the EU SME Instrument, progressing from a Phase 1 feasibility study in 2018 to a full Phase 2 development grant of over EUR 2 million. Their work sits at the intersection of photonics engineering and clinical dermatology, targeting the fast-growing aesthetic medicine market. As a small, IP-driven company, their core value is translating laser physics into safe, effective, CE-marked devices ready for clinical use.

What they specialise in

How they've shifted over time

In 2018, LightSense entered H2020 with a broad framing around laser technology for dermatologic healthcare — a concept-stage pitch typical of SME Phase 1. By 2019, after successful Phase 1 validation, they narrowed sharply to a specific clinical problem: pigmentation disorders treated through an aesthetic medical device. This is a textbook startup trajectory — start wide to validate the technology, then focus on the most commercially viable application. There is no ambiguity about the direction: they are building a specific product for a specific market, not doing open-ended research.

LightSense is on a product commercialization path — having completed Phase 2 funding by 2021, the logical next step is CE marking, clinical validation, and market entry in the EU aesthetic medicine sector.

How they like to work

LightSense has acted as coordinator on both of its H2020 projects, which is unusual and signals a company that owns its technology and leads its own agenda rather than joining others' consortia. With only one unique partner across two projects, they operate as a near-solo entity — consistent with a startup protecting its IP and driving commercialization independently. Anyone partnering with them should expect to enter their orbit, not the other way around.

LightSense has an extremely limited H2020 network: one unique partner in one country (UK). This reflects a deliberate focus on internal development rather than broad academic or industrial collaboration.

What sets them apart

LightSense is one of the few SMEs to have navigated the full SME Instrument pipeline — from a EUR 50K feasibility study to a EUR 2.1M Phase 2 grant — in a single coherent technology area, which demonstrates both scientific credibility and strong commercial framing. Their specific niche, laser treatment of pigmentation disorders, sits in a growing global market (aesthetic dermatology) with clear patient demand and limited competition from academic players. For a consortium needing a medical device partner with hands-on laser photonics and regulatory commercialization experience in aesthetics, LightSense offers a rare combination of technical depth and startup execution track record.

Highlights from their portfolio

• CLEAN SLATE
  The flagship project with EUR 2.1M in EC funding, representing one of the largest SME Instrument Phase 2 grants in aesthetic medical devices and the culmination of LightSense's H2020 technology development pathway.
• LIGHTSENSE
  The Phase 1 feasibility study that validated the laser dermatology concept and unlocked the follow-on EUR 2.1M grant — a rare successful Phase 1 → Phase 2 progression in the SME Instrument programme.